Targeted Compstatin Analogs for Long-Acting Complement Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing therapies for inhibiting complement activation are inadequate for various therapeutic purposes, particularly in conditions where complement-mediated disorders occur due to inappropriate or excessive activation, such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, ischemia/reperfusion injury, and transplant rejection.

Innovation Solution

Development of cell-reactive, long-acting, and targeted compstatin analogs that can be covalently or non-covalently attached to cells, tissues, or organs to inhibit complement activation, providing protection against complement-mediated damage for extended periods without the need for repeated treatments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If existing complement inhibitors are used to treat complement-mediated disorders, then complement activation is inhibited, but the duration of protection is insufficient requiring repeated treatments

Engineering Contradiction:

Improveduration of complement inhibitionVSAvoidtime between repeated treatments

Core Design Contradiction:

Duration of action of moving objectVSLoss of time

Solution Approach 1:

The compstatin analog is covalently attached to cells in advance before complement-mediated damage occurs, creating long-lasting protection that persists for at least two weeks without requiring repeated treatments. This preliminary conjugation ensures the inhibitor is already in place when complement activation threatens the cell.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The covalent attachment of compstatin analog to the cell creates continuous complement inhibition over an extended period (at least two weeks), maintaining protective action continuously rather than requiring intermittent reapplication of the inhibitor.

Inventive Principle:

Principle #20Continuity of useful action

2Duration of action of moving object

If compstatin analogs are covalently attached to cells to provide long-lasting protection, then duration of action is extended, but the complexity of the treatment protocol increases

Engineering Contradiction:

Improveduration of complement inhibitionVSAvoidcomplexity of conjugation protocol

Core Design Contradiction:

Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The cell essentially serves itself by being the target of the conjugation reaction. The compstatin analog is designed to specifically react with components on the cell surface, allowing the cell to become its own anchor point for the inhibitor, simplifying the overall system compared to requiring external delivery mechanisms.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The compstatin analog itself acts as the intermediary that bridges the therapeutic effect (complement inhibition) and the delivery mechanism (covalent attachment). By designing the analog with specific reactive groups, it mediates its own stable attachment to the cell while maintaining its inhibitory function.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If compstatin analogs are designed to be cell-reactive and targeted, then specificity of protection is improved, but the difficulty of identifying and characterizing the analogs increases

Engineering Contradiction:

Improvespecificity of cell protectionVSAvoiddifficulty of identifying and characterizing analogs

Core Design Contradiction:

Adaptability or versatilityVSDifficulty of detecting and measuring

Solution Approach 1:

The compstatin analog is designed with specific local properties: a compstatin core region that provides complement inhibition and a reactive region with specific functional groups that target particular cell surface components. This local differentiation enables selective attachment to desired cells while maintaining the inhibitory function.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The compstatin analog can be viewed as segmented into functional regions: the compstatin portion that binds and inhibits complement, and the reactive portion that enables covalent attachment to cell surface components. This segmentation allows independent optimization of each function and simplifies identification and characterization.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20260062448A1Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Publication Date: 2026.03.05 APELLIS PHARMACEUTICALS INC

AI summary

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.